Curious about EpiSwitch® CiRT’s role in cancer care? Hear about our first-of-its-kind blood test that helps predict immunotherapy response in The Immunobuddies podcast with Dr. Ricky Frazer & Dr. Anna Olsson-Brown. Learn more in our latest #InTheLoop blog post: mycirt.co/wcy. #cancer #immunotherapy #cancercare #EpiSwitchCiRT Dr. Bartu Ahiska Ryan Mathis, M.D.
About us
The EpiSwitch® CiRT (Checkpoint inhibitor Response Test) is a first-of-its-kind smart blood test for cancer patients that provides guidance on navigating the toughest challenges of immunotherapy like treatment planning, pseudo-progression, and adverse events. For more information, please visit MyCiRT.com. Follow us @EpiSwitchCiRT on Twitter.
- Website
-
www.mycirt.com
External link for EpiSwitch CiRT
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Oxford Business Park South, England
Updates
-
Proud to see EpiSwitch® CiRT featured in Health & Protection’s article about healthcare provider Bupa. Our test supports clinicians in determining the effectiveness of immunotherapy for cancer patients. Discover how genomics is transforming patient care at Bupa. #Cancer #Immunotherapy #CancerCare
-
With liver cancer survival rates often measured in months, especially for patients with advanced stages, the need for precise and effective treatment tools has never been greater. This Liver Cancer Awareness Month, we highlight our dedication to developing precision medicine tests that personalize care and help improve survival outcomes. #LiverCancerAwarenessMonth #LiverCancer
-
-
Check out the latest episodes of The Immunobuddies Podcast to hear about how the CiRT test helps patients going through immunotherapy: mycirt.co/immunobuddies. Ricky Frazer Dr. Bartu Ahiska Ryan Mathis, M.D. #cancer #immunotherapy
The Immunobuddies
buzzsprout.com
-
The Immunobuddies Podcast is talking EpiSwitch® CiRT! Tune in as Dr. Ricky Frazer and Dr. Anna Olsson-Brown discuss our immune checkpoint inhibitor response test with our very own Dr. Bartu Ahiska and Ryan Mathis, M.D.: https://lnkd.in/g23YPfAF. #Cancer #Immunotherapy #PersonalizedMedicine
PhD in Statistical Genomics, Oxford University | MEng with Distinction, Cambridge University | Senior Commercial Director, Oxford BioDynamics plc
In the latest The Immunobuddies Podcast, hosts Dr Ricky Frazer & Dr Anna Olsson-Brown lead an insightful discussion on the benefits of EpiSwitch CiRT. Across three episodes, guests Ryan Mathis, M.D. & Dr. Bartu Ahiska from Oxford BioDynamics Plc will explain how CiRT reports on the readiness of a patient’s immune system to work with #immunotherapy to fight their #cancer. https://lnkd.in/e9AhGGWc
-
The future of #immunotherapy lies in precision. Dr. Christopher Sweeney’s #ESMO24 presentation on the challenges in current trials reminds us how vital predictive tools are to maximize patient benefits and minimize costs. Personalized approaches will lead to more successful outcomes. #PersonalizedMedicine
-
-
With 85% accuracy, the EpiSwitch® CiRT blood test captures how the tumor, immune system, and genes interact to predict a patient’s response to immune checkpoint inhibitors (ICIs). Discover how it’s transforming #cancercare in our blog post: obdx.co/b54. #immunotherapy
-
-
EpiSwitch CiRT reposted this
We are embarking on a journey to identify patients likely to respond to Immunotherapy based on new and unique test Episwitch CIRT in a prospective real world evidence study (www.ccorn.net) to enable us to have a quick answer to start patients on highly effective I/O therapy. www.kashyappatel.net www.betweelifeanddeath.org www.cbcca.net
Colleagues and collaborators are thrilled about the advancement of the PROWES study, which is further elucidating the clinical application and utility of CiRT for use in multiple oncological indications. The IRB-approved study is enrolling up to 2,500 patients across many nationally recognized oncology institutions. Dr. Kashyap Patel, CEO and oncologist of Carolina Blood and Cancer Care Associates (primary trial site) highlights the impact of our very accurate (85%) CiRT test that predicts a patient's response to immune checkpoint inhibitors, giving physicians a powerful tool for patient care management. Learn more at obdx.co/pvz and tune into updates at #WorldCDx. #Cancer #Immunotherapy #ImmunoOncology #CancerCare
-
-
Colleagues and collaborators are thrilled about the advancement of the PROWES study, which is further elucidating the clinical application and utility of CiRT for use in multiple oncological indications. The IRB-approved study is enrolling up to 2,500 patients across many nationally recognized oncology institutions. Dr. Kashyap Patel, CEO and oncologist of Carolina Blood and Cancer Care Associates (primary trial site) highlights the impact of our very accurate (85%) CiRT test that predicts a patient's response to immune checkpoint inhibitors, giving physicians a powerful tool for patient care management. Learn more at obdx.co/pvz and tune into updates at #WorldCDx. #Cancer #Immunotherapy #ImmunoOncology #CancerCare
-
-
The CiRT test is transforming the #immunooncology landscape. Dive into a GenomeWeb Q&A article with OBD COO Thomas Guiell to learn about how CiRT predicts a patient’s response to immune checkpoint inhibitor (ICI) therapy, giving physicians a powerful tool for patient care management: obdx.co/r02. #cancer #immunotherapy
-